for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zeria Pharmaceutical Co Ltd

4559.T

Latest Trade

1,951.00JPY

Change

15.00(+0.77%)

Volume

119,200

Today's Range

1,921.00

 - 

1,955.00

52 Week Range

1,790.00

 - 

2,558.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,936.00
Open
1,940.00
Volume
119,200
3M AVG Volume
2.05
Today's High
1,955.00
Today's Low
1,921.00
52 Week High
2,558.00
52 Week Low
1,790.00
Shares Out (MIL)
46.92
Market Cap (MIL)
103,635.50
Forward P/E
26.14
Dividend (Yield %)
1.74

Next Event

Dividend For 4559.T - 17.0000 JPY

Latest Developments

More

Zeria Pharmaceutical: Bought Back 356,100 Shares For 731 Million Yen In Nov

Zeria Pharmaceutical says change in share repurchase plan

ZERIA PHARMACEUTICAL buys back 2.8 mln shares for totaling 5.69 bln yen

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zeria Pharmaceutical Co Ltd

ZERIA PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company operates in three business segments. The Ethical Pharmaceutical segment is principally involved in the manufacture, purchase and sale of ethical pharmaceutical products. The Consumer Healthcare segment is involved in the manufacture, purchase and sale of health food products and over-the-counter (OTC) drugs related to self medication, import and export of raw materials, as well as production and sale of cosmetics, among others. The Others segment is engaged in the insurance agency and real estate businesses, as well as the purchase and sale of promotional items. As of March 31, 2014, the Company had 17 subsidiaries.

Industry

Biotechnology & Drugs

Contact Info

10-11, Kobuna-cho, Nihonbashi

+81.3.36632351

http://www.zeria.co.jp

Executive Leadership

Sachiaki Ibe

Chairman of the Board, Chief Executive Officer, Representative Director

Mitsuhiro Ibe

President, Chief Operating Officer, Representative Director

Hirokazu Endo

Vice President, Chief Director of Administration, Director of Human Resources, Director of Legal Affairs, Director

Makoto Kishimoto

Managing Director, Chief Director of Production & Logistics

Hiroki Kato

Director of Pharmaceutical Sales, Director

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (JPY)

2017

66.730

2018

80.720

2019

69.560

2020(E)

74.650
Price To Earnings (TTM)
40.01
Price To Sales (TTM)
1.68
Price To Book (MRQ)
1.61
Price To Cash Flow (TTM)
16.88
Total Debt To Equity (MRQ)
65.53
LT Debt To Equity (MRQ)
14.42
Return on Investment (TTM)
3.17
Return on Equity (TTM)
2.11

Latest News

BRIEF-Zeria Pharmaceutical buys back 168,200 shares for 342.2 mln yen in March

* Says it repurchased 168,200 shares of its common stock for 342.2 million yen in total from March 1 to March 31

BRIEF- Zeria Pharmaceutical buys back 113,900 shares for 236.5 mln yen in February

* Says it bought back 113,900 shares for 236.5 mln yen in total from Feb. 1 to Feb. 28

BRIEF-Zeria Pharmaceutical says extension of share repurchase period

* Says it plans to extend share repurchase period to a deadline of May 11

BRIEF-Zeria Pharmaceutical buys back 150,900 shares for 345.4 mln yen in January

* Says it repurchased 150,900 shares of its common stock for 345.4 million yen in total from Jan. 1 to Jan. 31

BRIEF-Zeria Pharmaceutical buys back 32,000 shares for 66.9 mln yen

* Says it repurchased 32,000 shares for 66.9 million yen in total, from Dec. 1, 2017 to Dec. 31, 2017

BRIEF-Zeria Pharmaceutical buys back 39,100 shares for 82.3 mln yen

* Says it bought back 39,100 shares for 82.3 million yen in total, from Nov. 1 to Nov. 30

BRIEF-Zeria Pharmaceutical says extension of share repurchase period

* Says it extends share repurchase period to a deadline of Feb. 6, 2018, instead of Nov. 2 previously

BRIEF-Zeria Pharmaceutical to repurchase 6.8 pct shares

* Says it plans to repurchase up to 3.6 million shares, representing 6.8 percent of outstanding

BRIEF-Zeria Pharmaceutical ends license agreement with EA Pharma

* Says it ends a license agreement with EA Pharma Co Ltd, regarding proton pump inhibitor E3710

BRIEF-Zeria Pharmaceutical to repurchase 3.4 pct shares

* Says it will repurchase up to 1.8 million shares, representing 3.4 percent of outstanding

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up